The excessive release of
glutamate is a critical
element in the neuropathology of acute and chronic
brain disorders. The purpose of the present study was to investigate the effect and possible mechanism of
myricetin, a naturally occurring
flavonoid with a neuroprotective profile, on endogenous
glutamate release in the nerve terminals (synaptosomes) of the rat cerebral cortex. The release of
glutamate was evoked by the K(+) channel blocker
4-aminopyridine (4-AP) and measured by one-line
enzyme-coupled fluorometric assay. We also used a membrane potential-sensitive
dye to assay the synaptosomal plasma membrane potential, and a Ca(2+)
indicator Fura-2 to monitor cytosolic Ca(2+) concentrations ([Ca(2+)]C). Results show that
myricetin inhibited 4-AP-evoked
glutamate release, and this effect was prevented by chelating extracellular Ca(2+)
ions and the vesicular transporter inhibitor
bafilomycin A1. However, the
glutamate transporter inhibitor dl-threo-beta-benzyl-oxyaspartate had no effect on
myricetin action.
Myricetin did not alter the synaptosomal membrane potential, but decreased 4-AP-induced increases in the cytosolic free Ca(2+) concentration. Furthermore, the
myricetin effect on 4-AP-evoked
glutamate release was prevented by blocking the Cav2.2 (N-type) and
Cav2.1 (P/Q-type) channels, but not by blocking intracellular Ca(2+) release. These results suggest that
myricetin inhibits
glutamate release from cerebrocortical synaptosomes by attenuating voltage-dependent Ca(2+) entry. This implies that the inhibition of
glutamate release is an important pharmacological activity of
myricetin that may play a critical role in the apparent clinical efficacy of this compound.